Johnson & Johnson

NYSE:JNJ   3:59:58 PM EDT
170.36
+0.14 (+0.08%)
4:54:43 PM EDT: $170.35 -0.01 (-0.01%)
Products

J&J Announces Agreement In Principle With Gavi To Supply Janssen's COVID-19 Vaccine Candidate To Lower-Income Countries In 2021

Published: 12/18/2020 14:43 GMT
Johnson & Johnson (JNJ) - Johnson & Johnson Announces Agreement in Principle With Gavi to Supply Janssen's Covid-19 Vaccine Candidate to Lower-income Countries in 2021 to Lower-income Countries in 2021.
Will Provide Up to 500 Million Doses of Investigational Covid-19 Vaccine Candidate As Part of Agreement With Gavi, the Vaccine Alliance.
Doses Will Be Distributed Through 2022, If the Vaccine Candidate is Proven to Be Safe and Effective.
Co, Gavi Expect to Enter Into Apa That Would Provide Covax Facility With 100 Million Doses of Janssen's Covid-19 Vaccine Candidate in 2021.
Gavi Also Has Opportunity to Order Another 100 Million Doses in 2021, and Up to 300 Million Doses in 2022.